Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study)

Ryo Shimoyama, Susumu Hijioka, Nobumasa Mizuno, Gakuto Ogawa, Tomoko Kataoka, Hiroshi Katayama, Nozomu Machida, Yoshitaka Honma, Narikazu Boku, Tetsuya Hamaguchi, Haruhiko Fukuda, Masanori Terashima, Yukihide Kanemitsu, Junji Furuse